Castle Biosciences INC Form 4 insider transactions

Derek J Maetzold, Pres. & Chief Exec. Officer and a Director of Castle Biosciences Inc, sold 39,016 shares of common stock on August 4, 2026.

Derek J Maetzold, Pres. & Chief Exec. Officer and a Director of Castle Biosciences Inc, sold 9,836 shares of common stock on July 27, 2026.

Derek J Maetzold, Pres. & Chief Exec. Officer and a Director of Castle Biosciences Inc, sold 4,172 shares of common stock on July 14, 2026 for $22.92 per share.

Derek J. Maetzold, President & CEO of Castle Biosciences Inc., reported transactions involving the sale of common stock under a pre-arranged trading plan.

Castle Biosciences COO Kristen M. Oelschlager reported the sale of 8,186 shares of common stock for approximately $24.40 per share and 400 shares for approximately $24.78 per share, executed under a Rule 10b5-1 trading plan.

Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported a sale of common stock executed under a pre-arranged trading plan.

CEO Derek Maetzold sold shares of Castle Biosciences common stock on June 15, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Director Tiffany Olson was granted 11,766 restricted stock units in Castle Biosciences, Inc. as part of an equity compensation arrangement.

Director Ellen Goldberg was granted 11,766 restricted stock units in Castle Biosciences, Inc. as part of an equity compensation arrangement.

Director Miles Harrison was granted 11,766 restricted stock units by Castle Biosciences, Inc.

Director Rodney Cotton was granted 11,766 restricted stock units in Castle Biosciences, Inc. as part of an equity compensation arrangement.

Director Kim Caple was granted 11,766 restricted stock units as part of the company's equity compensation program.

Director Daniel Bradbury was granted 11,766 restricted stock units by Castle Biosciences, Inc. on May 28, 2026.

Director G. Bradley Cole was granted 11,766 restricted stock units by Castle Biosciences, Inc.

Castle Biosciences Director Bradley Cole acquired 13,667 Restricted Stock Units on May 22, 2026, as detailed in a Form 4 filing.

Castle Biosciences Director Daniel Bradbury acquired 13,667 Restricted Stock Units (RSUs) on May 22, 2026, which represent an equivalent number of common shares.

Miles Harrison, a Director at Castle Biosciences Inc., acquired 13,667 Restricted Stock Units on May 22, 2026.

Castle Biosciences Director Tiffany Olson acquired 13,667 Restricted Stock Units (RSUs) on May 22, 2026, as detailed in a Form 4 filing.

Castle Biosciences Director Ellen Goldberg acquired 13,667 Restricted Stock Units on May 22, 2026, increasing her beneficial ownership.

Castle Biosciences Director Kim Caple acquired 13,667 Restricted Stock Units on May 22, 2026, as detailed in a Form 4 filing.

Castle Biosciences Director Rodney Cotton acquired 13,667 Restricted Stock Units on May 22, 2026, which vest on the earlier of the one-year anniversary of the grant date or the day before the next Annual Meeting.

Castle Biosciences Chief Commercial Officer Juvenal Tobin W acquired 11,210 shares of common stock through the exercise of a stock option.

CEO Derek Maetzold sold shares of Castle Biosciences under a pre-established Rule 10b5-1 trading plan.

Derek J. Maetzold, President & CEO of Castle Biosciences, Inc., reported transactions involving common stock under a pre-arranged trading plan.

Derek J. Maetzold, President & CEO of Castle Biosciences, reported transactions involving common stock under a pre-arranged trading plan.

Castle Biosciences' President and CEO, Derek J. Maetzold, reported the exercise of stock options and subsequent sale of common stock under a pre-arranged Rule 10b5-1 plan.

Castle Biosciences Director Rodney Cotton acquired 5,329 shares of common stock through the exercise of Restricted Stock Units.

Castle Biosciences Inc. President and CEO Derek J. Maetzold reported the sale of 19,300 shares of common stock through a pre-arranged 10b5-1 plan.

Castle Biosciences' President and CEO, Derek J. Maetzold, sold over 30,000 shares of common stock in pre-scheduled transactions.

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, sold 20,863 shares of common stock for a weighted-average price of $25.24 per share.